Skip to main content

Table 3 Outcome measures

From: Allogeneic human umbilical cord-derived mesenchymal stem cells for severe bronchopulmonary dysplasia in children: study protocol for a randomized controlled trial (MSC-BPD trial)

MeasuresTime frames
Primary outcomesCumulative duration of oxygen therapyUntil the time of stopping oxygen therapy
Secondary outcomesAdverse eventsNumber of serious adverse eventsWithin 24 h post hUC-MSCs infusion
Acute infusion associated adverse eventsFrom the start of the trials to 1 month post hUC-MSCs infusion
Late infusion associated adverse eventsWithin 2 years post hUC-MSCs infusion
The rate of supplemental oxygen therapyAt 1 month post hUC-MSCs infusion
Duration of invasive mechanical ventilation 
Duration of noninvasive mechanical ventilation
The first time of stopping oxygen supplement
The rate of re-oxygen supplement
Pulmonary function changesAt 6, 12, and 24 months post hUC-MSCs infusion
Chest radiography changes
Blood oxygen saturationAt 1, 3, 6, 12, and 24 months post hUC-MSCs infusion
Mortality
Times of hospital readmissions
Complications of preterm birth